著者
Kenichi Watanabe Hiroshi Suzuki Meizi Jiang Shinya Tsukano Satoshi Kataoka Sueshi Ito Takatsugu Sakai Toru Hirokawa Hisanori Haniu Fujito Numano Satoshi Hoshina Satoshi Hasegawa Masamichi Matsunaga Kousei Chiba Naka Saito Hiroshi Yoshida Satoru Takami Soichiro Okubo Harunobu Hirano Akihiko Saitoh Hideaki Bujo
出版者
The Japanese Circulation Society
雑誌
Circulation Journal (ISSN:13469843)
巻号頁・発行日
pp.CJ-20-1271, (Released:2021-09-16)
参考文献数
23
被引用文献数
1

Background:Intimal smooth muscle cells (SMCs) play an important role in the vasculitis caused by Kawasaki disease (KD). Lipoprotein receptor 11 (LR11) is a member of the low-density lipoprotein receptor family, which is expressed markedly in intimal vascular SMCs and secreted in a soluble form (sLR11). sLR11 has been recently identified as a potential vascular lesion biomarker. sLR11 is reportedly elevated in patients with coronary artery lesions long after KD, but there is no description of sLR11 in acute KD. Our aim was to determine the sLR11 dynamics in acute KD and to assess its usefulness as a biomarker.Methods and Results:106 acute KD patients and 18 age-matched afebrile controls were enrolled. KD patients were classified into the following subgroups: intravenous immunoglobulin (IVIG) responders (n=85) and non-responders (n=21). Serum sLR11 levels before IVIG therapy were higher in non-responders (median, 19.6 ng/mL; interquartile range [IQR], 13.0–24.9 ng/mL) than in controls (11.9 ng/mL, 10.4–14.9 ng/mL, P<0.01) or responders (14.3 ng/mL, 11.7–16.5 ng/mL, P<0.01). Using a cutoff of >17.5 ng/mL, non-responders to initial IVIG therapy were identified with 66.7% sensitivity and 78.8% specificity.Conclusions:sLR11 can reflect the state of acute KD and might be a biomarker for patient response to IVIG therapy.

言及状況

外部データベース (DOI)

Twitter (9 users, 32 posts, 47 favorites)

#川崎病 患者さんの可溶性リポ蛋白質受容体11(sLR11) は初回IVIG不応(図A)、2回目IVIG不応(図B)の両者と相関していました。IVIG不応を予測し #冠動脈瘤 などの心合併症を防ぎたいですね
#川崎病 患者さんでは血清sLR11(可溶性リポ蛋白受容体11)はIVIG療法後に有意に上昇し、回復期は元より高いものの減少しました(図A)。IVIG不応例でのsLR11は、治療前から回復期までの全てのタイミングで反応例より高値でした(図B)。 #小児循環研究室 https://t.co/6qgPbH4iW3 https://t.co/b6JAz15pFe
#小児循環研究室 が可溶性リポ蛋白受容体11 (sLR11)を測定したところ、IVIG前の #川崎病 患者さんは対照群よりsLR11が高値でした。IVIGへの反応性や冠動脈瘤の有無で比較すると、IVIG不応例や冠動脈瘤の発生例でsLR11が高値でした。 https://t.co/6qgPbHllY3 https://t.co/qMURO1WGuZ
#川崎病 患者さんの急性期に、血管病変のマーカーとして期待されている可溶性リポ蛋白受容体11 (sLR11)の血清中の濃度を調べました。IVIG不応例において治療前の sLR11が反応例や対照群よりも高値であったことを昨年発表しています。#KawasakiDisease #小児循環研究室 https://t.co/6qgPbH4iW3
We evaluated serum soluble lipoprotein receptor 11 of #KawasakiDisease patients. Using a cutoff value of >17.6 ng/mL, we identified the non-responders (to a second dose of #IVIG) with a sensitivity of 73.3% and a specificity of 79.1%. #小児循環研究室 https://t.co/6qgPbH4iW3 https://t.co/XIlahKlyyW
In all #KawasakiDisease patients, serum soluble lipoprotein receptor 11 (#sLR11) levels were elevated after intravenous immunoglobulin therapy. There was a decreased but sustained high level in the convalescent stage. #Pediatrics #小児循環研究室 https://t.co/6qgPbH4iW3 https://t.co/OQMKbdPqV7
Serum soluble lipoprotein receptor 11 levels before intravenous immunoglobulin therapy were higher in all #KawasakiDisease patients. Serum #sLR11 levels before #IVIG therapy were higher in non-responders than in controls or responders. #小児循環研究室 https://t.co/6qgPbHllY3 https://t.co/gyEdHRO5UP
We evaluated soluble lipoprotein receptor 11 of #KawasakiDisease patients. Serum #sLR11 levels before intravenous immunoglobulin were higher in #IVIG non-responders than in responders or afebrile controls. #Pediatrics #PediatricCardiology #小児循環研究室 https://t.co/6qgPbHllY3
#長岡赤十字病院小児科 で小児循環器が専門の渡邉先生の論文が掲載されました! 川崎病の新しいバイオマーカーに関する報告です! 掲載おめでとうございます

収集済み URL リスト